These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 31805251)

  • 21. Brain tissue gadolinium retention in pediatric patients after contrast-enhanced magnetic resonance exams: pathological confirmation.
    Stanescu AL; Shaw DW; Murata N; Murata K; Rutledge JC; Maloney E; Maravilla KR
    Pediatr Radiol; 2020 Mar; 50(3):388-396. PubMed ID: 31989188
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Gadolinium deposition within the dentate nucleus and globus pallidus after repeated administrations of gadolinium-based contrast agents-current status.
    Stojanov D; Aracki-Trenkic A; Benedeto-Stojanov D
    Neuroradiology; 2016 May; 58(5):433-41. PubMed ID: 26873830
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Gadolinium Retention in Erythrocytes and Leukocytes From Human and Murine Blood Upon Treatment With Gadolinium-Based Contrast Agents for Magnetic Resonance Imaging.
    Di Gregorio E; Furlan C; Atlante S; Stefania R; Gianolio E; Aime S
    Invest Radiol; 2020 Jan; 55(1):30-37. PubMed ID: 31503081
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Gadolinium Retention and Breast MRI Screening: More Harm Than Good?
    Sardanelli F; Cozzi A; Trimboli RM; Schiaffino S
    AJR Am J Roentgenol; 2020 Feb; 214(2):324-327. PubMed ID: 31799869
    [No Abstract]   [Full Text] [Related]  

  • 25. Gadolinium Retention and Toxicity-An Update.
    Ramalho M; Ramalho J; Burke LM; Semelka RC
    Adv Chronic Kidney Dis; 2017 May; 24(3):138-146. PubMed ID: 28501075
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Subsequent MRI of pediatric patients after an adverse reaction to Gadolinium-based contrast agents.
    Hojreh A; Peyrl A; Bundalo A; Szepfalusi Z
    PLoS One; 2020; 15(4):e0230781. PubMed ID: 32243440
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Gadolinium Retention: A Research Roadmap from the 2018 NIH/ACR/RSNA Workshop on Gadolinium Chelates.
    McDonald RJ; Levine D; Weinreb J; Kanal E; Davenport MS; Ellis JH; Jacobs PM; Lenkinski RE; Maravilla KR; Prince MR; Rowley HA; Tweedle MF; Kressel HY
    Radiology; 2018 Nov; 289(2):517-534. PubMed ID: 30204075
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Breakthrough Hypersensitivity Reactions to Gadolinium-based Contrast Agents and Strategies to Decrease Subsequent Reaction Rates: A Systematic Review and Meta-Analysis.
    Walker DT; Davenport MS; McGrath TA; McInnes MDF; Shankar T; Schieda N
    Radiology; 2020 Aug; 296(2):312-321. PubMed ID: 32427558
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Integration of gadolinium in nanostructure for contrast enhanced-magnetic resonance imaging.
    Marasini R; Thanh Nguyen TD; Aryal S
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2020 Jan; 12(1):e1580. PubMed ID: 31486295
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Gadolinium-based contrast agents and nephrogenic systemic fibrosis: why did it happen and what have we learned?
    Weinreb JC; Abu-Alfa AK
    J Magn Reson Imaging; 2009 Dec; 30(6):1236-9. PubMed ID: 19938035
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Gadolinium deposition disease (GDD): Does the missing link exist? -A suggested pathologic model.
    Boehm IB
    Eur J Intern Med; 2022 Nov; 105():118-120. PubMed ID: 35864076
    [No Abstract]   [Full Text] [Related]  

  • 32. Gadolinium Deposition in the Brain: A Systematic Review of Existing Guidelines and Policy Statement Issued by the Canadian Association of Radiologists.
    Costa AF; van der Pol CB; Maralani PJ; McInnes MDF; Shewchuk JR; Verma R; Hurrell C; Schieda N
    Can Assoc Radiol J; 2018 Nov; 69(4):373-382. PubMed ID: 30249408
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Survey of gadolinium-based contrast agent utilization among the members of the Society for Pediatric Radiology: a Quality and Safety Committee report.
    Blumfield E; Moore MM; Drake MK; Goodman TR; Lewis KN; Meyer LT; Ngo TD; Sammet C; Stanescu AL; Swenson DW; Slovis TL; Iyer RS
    Pediatr Radiol; 2017 May; 47(6):665-673. PubMed ID: 28283728
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The use of gadolinium-based contrast agents in Ghana with a focus on residual intracranial gadolinium deposition.
    Piersson AD; Gorleku PN
    Radiography (Lond); 2018 Aug; 24(3):e51-e55. PubMed ID: 29976344
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Preventive Effect of Changing Contrast Media in Patients With A Prior Mild Immediate Hypersensitivity Reaction to Gadolinium-Based Contrast Agent.
    Ryoo CH; Choi YH; Cheon JE; Yoon SH; Kang HR; Park SJ; Lee W
    Invest Radiol; 2019 Oct; 54(10):633-637. PubMed ID: 31033674
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Gadolinium Brain Deposition after Macrocyclic Gadolinium Administration: A Pediatric Case-Control Study.
    Tibussek D; Rademacher C; Caspers J; Turowski B; Schaper J; Antoch G; Klee D
    Radiology; 2017 Oct; 285(1):223-230. PubMed ID: 28640695
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Are some agents less likely to deposit gadolinium in the brain?
    Radbruch A
    Magn Reson Imaging; 2016 Dec; 34(10):1351-1354. PubMed ID: 27629022
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Gadolinium contrast agents - are they really safe?
    Malikova H; Holesta M
    J Vasc Access; 2017 Mar; 18(Suppl. 2):1-7. PubMed ID: 28362042
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Acute Adverse Events Following Gadolinium-based Contrast Agent Administration: A Single-Center Retrospective Study of 281 945 Injections.
    McDonald JS; Hunt CH; Kolbe AB; Schmitz JJ; Hartman RP; Maddox DE; Kallmes DF; McDonald RJ
    Radiology; 2019 Sep; 292(3):620-627. PubMed ID: 31264948
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.